Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Sep 26, 2022 9:43pm
142 Views
Post# 34988339

RE:RE:RE:RE:RE:RE:RE:RE:RE:New corporate presentation

RE:RE:RE:RE:RE:RE:RE:RE:RE:New corporate presentationI think that's pretty obvious.  The huge increase in followers on Stocktwits and the increase in messages should be enough to prove that today's trading activity was entirely retail investor driven.  Especially, since that came off the heels of the release of that mention from ZipTrader.  People are posting questions like "How much can this pop if approved?"  They are all referencing the 3rd and likely coming for the 50K+ views of ZipTrader video.  That's the power of retail.  That's what THTX has not tapped into or managed expectations.  THTX has a huge opportunity to drop some news that gets the market talking and feed into the increased awareness.  If they don't, every one of these new investors will disappear after the 3rd.  The price will decline exponentially, but the good news is that we have some time for the hype to drive the price up quite a bit higher before the 3rd.  All eyes on THTX management now to do something with this opportunity.  And it may just be pure luck, but they actually have the opportunity to do it with a series of potential announcements coming.  They completely botched that opportunity last time.

palinc2000 wrote:

How can you tell the trading today in the US was from retail? 

I really thought that thru IR and other sources some investors have finally realized that the market cap did not even represent the value of existing legacy drug sales So the current SP does not take into account any increase in legacy drugs sales nor any potential positive development in the pipeline.

No downside and only upsides is a great investment thesis if you concur with that opinion

Why today?
I think it has been in the works for the past few weeks

 

 

scarlet1967 wrote:

 

2790bafc-6443-4aed-a90c-1cb2957c3330

2790bafc-6443-4aed-a90c-1cb2957c3330

 

https://www.theratech.com/static-files/8d86c08a-229e-4e9c-8ad2-ef353b8a4fbf

 

“Part 1 of the study is currently open to recruitment only in the USA.  Once MTD, RD and safety are established, part 2 (expansion) will open in sites in the USA, UK, and Europe.”

 

https://www.theratech.com/medicines-pipeline/pipeline-and-science/oncology/clinical-trials

 

I can’t see anything new apart from SP and market cap.

I don’t look often at the website but there is a patient information page for Oncology , Hepatology which might not be new?

 

https://www.theratech.com/medicines-pipeline/pipeline-and-science/oncology/patient-need

 

https://www.theratech.com/medicines-pipeline/pipeline-and-science/hepatology/patient-need

 

Even mentioning opening sites in the USA, UK and Europe might not be new but they are there so it will be interesting when and how many more sites if any will start enrolling. The intraday volume increased significantly today and now there are more than there are more than 1000 followers on Stocktwits which must be record as long as I remember. Both are positive developments in my opinion so a bit more exposure, more liquidity, less volatility etc. Hopefully this is the start of an ongoing trend going forward. 

I have said it many and too few times don’t underestimate the power of the retail investors!

 





<< Previous
Bullboard Posts
Next >>